XTLB

XTL Biopharmaceuticals Ltd. NASDAQ Listed Sep 1, 2005

Healthcare ·Biotechnology ·IL · xtlbio.com

$2.67

Mkt Cap $6.3M

52w Low $2.12 6.7% of range 52w High $10.28

50d MA $2.70 200d MA $3.96

P/E (TTM) -0.4x

EV/EBITDA -0.7x

P/B 0.1x

Debt/Equity 0.0x

ROE —

P/FCF -0.5x

RSI (14) —

ATR (14) —

Beta 0.68

50d MA $2.70

200d MA $3.96

Avg Volume 1.9M

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

SIC Code

2834

CIK (SEC)

1023549

Phone

972 3 611 6600

5 Badner Street · Ramat Gan, NY 5218102 · IL

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Dec 29, 2025	AMC	—	-0.36	—	2.69	+8.6%	+3.3%	-16.5%	+3.4%	+5.8%	+8.3%	—
Jun 30, 2025	AMC	—	0.10	—	4.56	+0.9%	+3.5%	+1.7%	+10.0%	-7.6%	+0.8%	—
Jan 1, 2025	AMC	—	-0.04	—	—	—	—	—	—	—	—	—
Dec 30, 2024	AMC	—	-0.13	—	7.44	-7.5%	+9.1%	-3.0%	+6.1%	-3.3%	-2.5%	—
Sep 26, 2024	AMC	—	-0.07	—	10.12	-2.8%	+1.2%	-6.2%	+1.2%	-4.1%	+3.0%	—
May 13, 2024	AMC	—	0.10	—	11.68	-0.7%	-12.0%	+6.6%	-3.3%	+1.5%	-3.3%	—
Mar 27, 2024	AMC	—	-0.14	—	10.80	-2.2%	+4.1%	+7.1%	-6.3%	+18.1%	-6.6%	—
Nov 15, 2023	AMC	—	-0.04	—	3.60	-10.8%	+8.9%	+5.1%	-2.9%	+3.0%	+0.0%	—
Aug 10, 2023	AMC	—	-0.07	—	3.16	+0.0%	+0.0%	+6.3%	+12.8%	+1.3%	+0.5%	—
May 16, 2023	AMC	—	-0.17	—	5.20	-7.7%	+2.3%	-2.3%	+1.5%	-1.5%	-1.5%	—
Mar 22, 2023	AMC	—	-0.14	—	4.72	+3.4%	+3.4%	-0.8%	+0.0%	+6.6%	-6.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 8	H.C. Wainwright	Maintains	Buy → Buy	—	$40.40	$44.00	+8.9%	+11.4%	-1.3%	-2.7%	-0.5%	-0.5%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.40	$44.00	+8.9%	+11.4%	-1.3%	-2.7%	-0.5%	-0.5%

Data updated apr 27, 2026 10:57am · Source: massive.com